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nfectiousness. The occurrence, severity and duration of
ymptoms are predictive factors of clinical deterioration.
e report here the epidemiological, clinical, virological and
mmunological characteristics of a cohort of patients with
HI.
Methods: Prospective observational study of patients
ith PHI at the Emilio Ribas Institute of Infectious Dis-
ases, a tertiary hospital in Sao Paulo, Brazil. Inclusion
riteria included negative or undetermined HIV-1 serology
ssociated with viral detection, or clinical and serological
vidence of seroconversion during the last 6 months. Epi-
emiological history, clinical data, HIV-1 plasma viral load,
D4 cell count, genotypic resistance testing, serology for
epatitis B, C, A, toxoplasmosis, cytomegalovirus, herpes
nd syphilis were recorded as well as the use of highly active
ntiretroviral treatment (HAART).
Results: Between 2007 and 2009, 10 patients met the
nclusion criteria (8 males and 2 females, median age
as 34). Two patients were asymptomatic and eight were
ymptomatic. The main symptoms were fever (80%), myal-
ia (60%), rash (30%), hepatitis (20%) aseptic meningitis
20%) and renal failure (10%). Only 4 patients had a
ononucleosis-like illness. Homosexual transmission route
as more frequent (60%). Five patients had plasma viral
oad above the upper limit of detection and the median
D4 cell count was 395cel/mm+ (range: 47—835cel/mm+).
ive patients received HAART and among 5 patients who
id not receive HAART, 2 patients had clinical and immuno-
ogical criteria for initiating HAART after 12 months of
ollow-up. Genotypic resistance testing was available for 4
atients. Overall patients had triple class susceptible HIV-
sub-type B strain. One patient had primary resistance to
on-nucleoside reverse transcriptase inhibitors and several
rotease inhibitors mutations and this ﬁnding was correlated
ith clinical severity.
Conclusion: Clinical, virological and immunological
arameters in PHI may be heterogenous, atypical clinical
resentation is frequent. Determinating resistance proﬁle is
seful for early therapeutic intervention, which is associated
ith better outcome.
oi:10.1016/j.ijid.2010.02.1657
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revalence of metabolic syndrome and estimated Fram-
ngham risk score among Brazilian HIV-infected patients
. Margareth1,∗, E.L. Dorea2, I.M. Bensenor3, I.R.S.
liveira2, G.A. Pinto2, A.L. Sassaki 2, P.A. Lotufo3
Instituto de Infectologia Emílio Ribas, Sao Paulo, Brazil
Hospital Universitário, University of Sao Paulo, Sao Paulo,
razil
Faculdade de Medicina, University of Sao Paulo, Sao Paulo,
razil
Background: Recent studies suggest that HIV infection
tself or combination ART (cART) were both associated with
ncreased risk for cardiovascular disease (CVD). The 10-year
ramingham risk score (FRS) is used to predict cardiovascular
vents in the non-HIV-infected patients, and its applica-
ion in the HIV-infected subjects is under discussion. We
valuated the traditional CVD risk factors and metabolic
s
g
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yndrome (MS) components among HIVinfected patients ART-
reated and ART-naïve.
Methods: This was a cross-sectional study of HIV-infected
ubjects ART-treated (n = 29), HIVinfected patients ART-
aive (n = 28) and controls without previous CVD events
n = 32). Subjects were selected for common age range
20 to 69 years) from the Instituto de Infectologia Emilio
ibas, São Paulo. We assessed cardiovascular risk factors,
IV viral load, nadir CD4 count, high-sensivity C-reactive
rotein (hs-CRP) and plasma lipid concentrations. MS compo-
ents included low LDL cholesterol, high triglycerides, high
MI, hypertension and diabetes. The statistical analysis were
one using a SPSS 16.0.
Results: Groups were matched for age (mean 43.6 years
or ART-treated vs 42.0 years for ART-naïve vs 42.8 for con-
rols); 31%, 35.7% o and 46.8% are women, respectively.
he mean duration of HIV infection was 10 years for ART-
reated and 6 years for ART-naïve subjects. The mean nadir
D4 count (cells/L) was 208 for ART-treated and 449
or ARTnaïve subjects (p < 0.0001); current HIV-RNA levels
ere undetectable on ART-treated and 13.683 copies/ml on
RT-naïve subjects (p = 0.005). There were no signiﬁcant dif-
erences between the groups in levels of hs-CRP, HDL and
DL-cholesterol. Total cholesterol was higher in ART-treated
han in ART-naïve (mean 209 vs 182mg/dl, respectively;
= 0.02); triglycerides was higher in ART-treated than in
RT-naïve subjects (mean 234 vs 137mg/dl, respectively;
= 0.02). Hypertension was more frequent in ART-treated
ompared to the others groups (p = 0.01). 41.4% of ART-
reated patients had MS, compared to 25% of ARTnaïve and
8.1% of controls (p = 0.0001); 27.6% of ART-treated had a
igh (> 20%) 10-year FRS compared to 0% in the others groups
p < 0.0001).
Conclusion: Our results shows a high prevalence of MS
nd high FRS in HIV-patients under treatment, which can
e used to predict cardiovascular risk stratiﬁcation in this
opulation.
oi:10.1016/j.ijid.2010.02.1658
7.023
actors affecting acceptance of HIV testing among ante-
atal care attendees in Ethiopia: With emphasis on role
f male partners
. Zewde
EngenderHealth, Hawassa, Ethiopia
Background: Counselling and testing is an entry point for
MTCT of HIV infection. To increase uptake of PMTCT inter-
entions and to beneﬁt more generally from HIV testing, the
reater involvement of men is important. This study was
esigned to assess factors affecting acceptance of HIV test-
ng among antenatal care (ANC) attendees with emphasis on
ole of male partners, in Wolaita zone, southern Ethiopia.
Methods: Cross-sectional study was conducted on 412
regnant women using structured questionnaire from March
o April 2008 in three public health centers of Wolaita zone,
outhern Ethiopia. The study was complimented and trian-
ulated by focus group discussions (FGDs). In the absence of
imilar study, the sample size was determined based on the
ssumption that 50% of women would make joint (with their
trac
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partner) decisions about HCT. The margin of error was set
at 5% and degree of conﬁdence 95%.
Results: Acceptance of HIV testing among the inter-
viewed pregnant women was 74.5%. Stigma and discrimina-
tion by the community, husband reaction and fear of positive
test result were reasons that impede higher acceptance
of HIV testing. Acceptance of HIV testing was signiﬁcantly
associated with pregnant women who had attended formal
education, reside in urban area, living with their partners
and those mentioned ART as PMTCT. Only 27% of pregnant
women could decide independently on accepting HIV test-
ing. Male partners, who came to health centers along with
their partners for ANC and HIV testing, were only 5.1%. Two
third of the study participants (65.5%) have no habit of open
discussion on HIV/STI with their male partners. Most women
with positive test result do not disclose their test result to
their partners. Pregnant women who could get partner sup-
port with positive test result were more likely to accept HIV
testing than their counterparts.
Conclusion: HIV testing acceptance is encouraging but
men’s involvement was found to be low and they appear
to be the secrete ingredient of PMTCT intervention. Gen-
erally, pregnant women need their male partners’ positive
attitude and support to accept HIV testing. Hence PMTCT
programs should give emphasis on involvement of male
partners.
doi:10.1016/j.ijid.2010.02.1659
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Attitudes towards neonatal male circumcision among His-
panic men and women in Miami, Florida
J.G. Castro1,∗, D. Jones2, I. Barradas2, M. Lopez1, S. Weiss2
1 University of Miami, Miami Shores, FL, USA
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Background: Hispanics in the U.S. with the lowest rates
of circumcision (MC) and relatively higher rates of hetero-
sexual HIV transmission may beneﬁt with higher rates of MC.
Before interventions to promote MC can be introduced in the
Hispanic community, additional information is necessary to
determine the factors that are related to its acceptability
in this population.
Methods: We conducted a qualitative study to assess the
attitudes towards neonatal MC in Hispanic pregnant females
and males and intensive interviews with 12 providers of the
Hispanic community. Gender concordant focus groups were
held to address the relative acceptability of MC. Each focus
group (2 male, 4 female) was lead by 2 trained facilita-
tors (medical, psychosocial). Key informants of the Hispanic
community had an individualized indepth structured inter-
views.
Results: Qualitative data was analyzed for dominant
themes and collapsed into overarching themes. Thirteen
themes emerged, including acceptability, appearance, cir-
cumcision and children, circumcision and HIV, cost, cultural
differences, health beneﬁts, knowledge and personal expe-
riences, pain and injury to the penis, perceived HIV risk,
religion, sexual performance and sexual pleasure. Men
associated acceptability with the attitudes of health care
professionals, knowledge about the procedure and hygiene.
-
s
c
tts e77
omen focused on cost, cultural differences, circumcised
amily members and decision making for circumcising chil-
ren. Attitudes regarding MC differed between national/
ultural group and gender; excepting the Mohel, Hispanic
ale providers related MC acceptability to American Pedi-
tric Association guidelines, personal circumcision status
nd were skeptical regarding its health beneﬁts for STD/HIV
isk reduction. Female providers focused on the ﬁnancial
urden to parents in its provision to neonates, lack of
nformation and the need to increase acceptability among
ispanic men.
Conclusion: Both women and men appeared accepting
f neonatal circumcision, and the women were assertive
egarding their role as decision makers regarding the pro-
edure.
oi:10.1016/j.ijid.2010.02.1660
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atients with newly-diagnosed HIV in 2004 versus 2008:
o apparent difference in progression
. Brown1,∗, C. Ní Bhuachalla1, C. de Gascun2, R. Hagan3,
. Bergin1
St. James’s Hospital, Dublin, Ireland
National Virus Reference Laboratory, Dublin, Ireland
National Blood Transfusion & Histocompatibility Service,
ublin, Ireland
Background: Trends have recently been observed suggest-
ng more rapid progression in newly-diagnosed HIV-positive
atients. This data is limited by an inability to speciﬁ-
ally identify the time of infection. Our HIV-positive cohort
isplays heterogenous acquisition risk and signiﬁcant immi-
ration from countries of high prevalence, and is ideal to
tudy changing epidemiology.
Methods: A retrospective cohort study was undertaken
omparing newly diagnosed HIV patients attending in the
rst half of 2004 with those in 2008. Baseline demograph-
cs and virological parameters were gathered. Progression
as followed for the ﬁrst year after diagnosis. Patients
ith known seroconversion were of particular interest —
ncluding those certain of time of infection, who recalled sig-
iﬁcant seroconversion illness and/or a negative test within
he preceding 6 months. Others with previous negative tests
utside this window were not designated as known serocon-
erters. Rapid progressors (RPs) were deﬁned as those with
ocumented seroconversion window< 2 years prior to pre-
entation, who progressed to CD4 ≤350 cells/mm3 within
rst year of follow-up. Results were analysed using Graph-
adInStat.
Results: Of the 200 charts reviewed, 96 met inclusion
riteria. Baseline characteristics are summarized in Table 1.
D4 ≤350 cellls/mm3 at ﬁrst presentation in 2004 and 2008
espectively was seen in 20(48%) and 31(57%) p = 0.42. CD4
ount ≤350 by end of year 1 was 25(60%) vs 35(65%) p = 0.67.
ean change in CD4% from diagnosis to end of year 1 or pre-
RT was -2.9%(SD5.1) vs +7.2%(SD 11.0) p < 0.0001 (95%CI,
13.7718 to -6.4882). AIDS-deﬁning illness in ﬁrst year was
een in 6(14%) vs 7(13%) p = 1.0. Of those with CD4 ≥350
ells/mm3 at ﬁrst presentation, 18 (82%) vs 18 (78%) main-
ained CD4 ≥350 at end of year 1 untreated. Of those with
